Scilex Holding Announces Strong ZTlido Sales Growth After Successful Post-Merger Integration ZTlido® gross sales grew from approximately $1 million in March to $2.4 million in April and $3.3 million in MaySP-102 pivotal phase 3 trial remains on track for completion in H1 2020ZTlido® 5.4% (3 X...

Scilex Announces ZTlido® Insurance Coverage for ~100 Million Insured Lives(1) SAN DIEGO, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Scilex Pharmaceuticals Inc. (SCILEX), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE), today announced that ZTlido® (lidocaine topical system)...

Scilex Announces Addition of ZTlido® to Express Scripts National Formularies SAN DIEGO, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Scilex Pharmaceuticals Inc. (SCILEX), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE), today announced that Express Scripts has added ZTlido®...

Sorrento Therapeutics Subsidiary, Scilex, Raises $140 million in Non-Dilutive Royalty-Based Financing to Support the Commercialization of Non-Opioid ZTlido™ Pain Medication SAN DIEGO, Sept. 10, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (“Sorrento”) announced today that its majority-owned subsidiary, Scilex Pharmaceuticals Inc. (“Scilex”),...

Hisamitsu America, Manufacturers of the Best-Selling Lidocaine Patch, Expand Lidocaine Line With New Cream and Roll-On Liquid Products FLORHAM PARK, N.J., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Hisamitsu America, a division of Hisamitsu Pharmaceutical Co., Inc., and the manufacturers of the popular, unscented Salonpas® Lidocaine 4% Pain...